The Latest Breaking News from ABBV

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

MarketBeat · Jan 31, 2025

AbbVie's Quarterly Earnings Preview: What You Need to Know

Pharma giant AbbVie is gearing up to announce its fourth-quarter results later this month and analysts expect a double-digit drop in earnings.

Barchart · Jan 16, 2025

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…

StockNews.com · Jan 8, 2025

3 Healthcare ETFs for a Balanced Investment Approach

For investors seeking a balanced approach, healthcare ETFs offer a combination of stability and growth potential. Therefore, it might be wise to consider Fidelity MSCI Health Care Index ETF (FHLC), iShares U.S. Healthcare ETF (IYH), and Vanguard Health Care Index Fund ETF Shares (VHT) for a balanced approach. Keep reading….

StockNews.com · Dec 6, 2024

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Benzinga · Dec 4, 2024

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga · Dec 3, 2024

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Barchart · Dec 3, 2024

Spotlight on AbbVie: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).

Benzinga · Nov 29, 2024

3 Healthcare Stocks Leading the Fight Against Global Diseases

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in established healthcare stocks, Pfizer (PFE), Merck & Co (MRK), and AbbVie (ABBV), presents a compelling opportunity to capitalize on the sector’s landscape. Read on….

StockNews.com · Nov 29, 2024

Market Whales and Their Recent Bets on ABBV Options

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Benzinga · Nov 25, 2024